Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Verstovsek, S.; Mesa, R.; Gotlib, J.; Levy, R.; Gupta, Vikas; Dipersio, J.; Catalano, J.; Deininger, M.; B. Miller, Carole; Silver, R.; Talpaz, M.; Winton, E.; Harvey, J.; Arcasoy, M.; Hexner, E.; Lyons, R.; Raza, A.; Vaddi, K.; Sun, William; Peng, W.; Sandor, V.; Kantarjian, H.

doi:10.3324/haematol.2014.115840

Public

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Shared by NobleBlocks on Dec 1, 2013 • 12:00 AM UTC

Authors:

S. Verstovsek

R. Mesa

J. Gotlib

Abstract

In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk my...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!